Investigation of mechanisms of drug resistance in malignant brain tumor stem cells
Project/Area Number |
21591880
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Cerebral neurosurgery
|
Research Institution | Kyorin University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
NAGANE Motoo 杏林大学, 医学部, 教授 (60327468)
|
Research Collaborator |
SHIMIZU Saki 杏林大学, 医学部, 実験助手
HARA Yukiko 杏林大学, 医学部, 講師 (40313267)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 脳腫瘍幹細胞 / 悪性脳腫瘍 / 薬剤耐性 / neurosphere / CD133 / temozolomide / アポトーシス / 悪件脳腫瘍 |
Research Abstract |
Forty malignant glioma specimens were subjected to tissue culture to establish new clones of brain tumor stem cells(BTSC) in our laboratory, of which 10 samples formed neurosphere and 4 are expected to established as BTSC expressing stem cell markers, such as nestin. X01S, an established BTSC clone, developed intracerebral tumors when inoculated, and was resistant to temozolomide(TMZ) as well as apoptosis-inducing targeted therapeutics in vitro, whereas TMZ elongated survival of mice bearing intracerebral X01S xenografts. MGMT gene promoter was methylated in three out of four BTSC cells including X01S, suggesting that multiple complex pathways might be involved in regulation of TMZ sensitivity in BTSCs.
|
Report
(4 results)
Research Products
(31 results)